IV ibuprofen market buoyed by improvements in drug delivery

A recent report from MarketIntelReports — ‘World Intravenous (IV) Ibuprofen Market — Opportunities and Forecast 2022’ — has estimated that the IV ibuprofen market will register a compound annual growth rate of 20% until 2022.

IV ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) used to reduce or treat pain, fever and inflammation as a result of disease, operative procedures or trauma and acute illness. IV ibuprofen is the preferred route of administration for the management of postoperative and acute pain. Demand for ibuprofen has increased because of the side effects of opioid analgesics, such as respiratory depression, allergic reactions, sedation and gastrointestinal events.

Advantages associated with IV ibuprofen, such as rapid result and targeted drug delivery, have resulted in the growth of this market. In 2015, the FDA approved the use of IV ibuprofen in paediatric patients, which is expected to be a considerable factor in the growth of this market in the forecasted period.

Other factors affecting growth include increasing incidence of cancer, cardiovascular ailments, pain, headache, toothache, back pain, arthritis, trauma and a shifting trend towards the use of non-opioid drugs.